- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04895852
Clinical Study of TEAS Intervention in Relieving Anxiety Before Thoracoscopic Surgery
Efficacy and Safety of Transcutaneous Electrical Acupoints Stimulation for Preoperative Anxiety in Thoracoscopic Surgery: Study Protocol for a Randomized Controlled Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
This single center, randomized, sham-controlled, participant-blinded and assessor-blinded trial will be conducted at the inpatient ward of cardiothoracic surgery department of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine. The trial will commence after ethical approval has been obtained and the protocol has been registered. Patient enrollment started in late June 2021 and is expected to end in March 2023. An estimated 92 participants will be recruited and randomly assigned to receive TEAS or sham TEAS (STEAS) in a l:l ratio using SPSS 21.0 software. During the development of the standard protocol, the Standards for Reporting Interventions in Clinical Trials for Acupuncture (STRICTA) and the SPIRIT reporting guidelines will be followed to explicitly and transparently explain the therapeutic processes involved.
Patients who will undergo VATS for pulmonary nodules will be screened. . Potential subjects will be interviewed preoperatively by the clinical research coordinator to assess whether they meet the inclusion and exclusion criteria. Eligible participants will voluntarily provide written informed consent prior to randomization.
This study will have a single-blind design. The patients are blinded to the group assignment and are told that they might or might not feel a sensation when the TEAS is working. Both acupoint stimulations in the TEAS group and in the STEAS group will be performed by the same acupuncturist who is not involved in the process of data collection. The TEAS instrument is covered with an opaque box for adequate blinding. The randomized numbers were generated with SPSS 21.0 (IBM®SPSS®Statistics, Version 21) software. The random sequence for group classification will be sealed in a confidential envelope. Patients will be randomly allocated into the TEAS group or STEAS group at a ratio of 1:1. Group assignment was exposed from a sealed envelope only by an acupuncturist. Patients will be treated separately to prevent communication. Efficacy evaluation will be conducted blinded to the grouping allocation. The efficacy evaluators and statisticians will be separated and blinded. To test the participant-blinding effects, all participants will be asked to guess whether they had received TEAS or STEAS within 5 minutes after one of the treatment sessions before VATS.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Xindi Wu
- Phone Number: 021-65161782
- Email: cindywu1111@126.com
Study Locations
-
-
-
Shanghai, China
- Recruiting
- Shanghai Yueyang Integrated Medicine Hospital
-
Contact:
- Jia Zhou
- Phone Number: 021-65161782
- Email: pdzhoujia@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Those diagnosed as pulmonary nodules requiring VATS.
- Age between 18 and 75 years old.
- 4 ≤ GAD-7 score ≤ 9 and those who have no previous mental illness and have not used anti-anxiety or psychotropic drugs within 2 weeks.
- Those who have clear consciousness, normal understanding, no expression barriers, can cooperate with treatment and have signed an informed consent.
- Patients who have not received TEAS treatment in the past.
- Patients who have not participated or participating in other clinical trials one month before enrollment.
Exclusion criteria
- Patients with skin infections in local meridian points.
- Patients with upper or lower limb nerve injury.
- Patients who had been implanted pacemaker.
Rejection, suspension and dropout criteria
- Those with serious adverse reactions.
- Those who presented worsen symptoms or life-threatening illnesses that cannot be continued during treatment.
- The principal investigator asserts that there are unacceptable risks for serious adverse events during the study.
- Patients who cannot cooperate to complete the research plan, including language difficulties, infectious diseases and other medical history.
- Patients quit by themselves.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TEAS group
30 minutes TEAS therapy on DU20, EX-HN3, LI4, LR3 once per day for three days before surgery.
|
The self-adhesive gel electrode pad will be placed at the center of DU20 (Baihui), EX-HN3 (Yintang) and both sides of LI4 (Hegu), LR3 (Taichong) in strict accordance with the World Health Organization Standardized Acupuncture Location.
Electric stimulation will be used with a TEAS apparatus (HANS200A Beijing Huawei Co., LTD.) .
The frequency of the electrical stimulation will be set as alternating 2/100Hz to relieve anxiety.
The current intensity will be adjusted individually, starting at 1 mA and increasing gradually until the patient can perceive and tolerate it (preferably slight twitching of local muscles without pain).
|
Sham Comparator: Control group
The control group selects the same acupoints as the TEAS group and other intervention measures are the same as the TEAS group except for the current intensity is set to 0-mA.
|
The STEAS group selects the same acupoints as the TEAS group and other intervention measures are the same as the TEAS group except for the current intensity is set to 0-mA.
The acupuncturist responsible for the operation will tell patients in STEAS group that this is a type of stimulus without perception.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Score change of Generalized Anxiety Scale (GAD-7)
Time Frame: up to 3 days before surgery
|
Add the scores of each of the 7 items to get the total score; among them, 0-4 points for no anxiety, 5-9 points for possible mild anxiety, 10-14 points for possible moderate anxiety, 15 Scores above are likely to have severe anxiety.
The GAD-7 scores' Change between three days before and the day before surgery will be recorded.
|
up to 3 days before surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
5-HT(µmol/L)
Time Frame: on the third day before the treatment and the day before the operation
|
The blood of each group of patients was collected on the third day before the treatment and the day before the operation, and the levels of neurotransmitter indexes (5-HT, NE, GABA) in the peripheral blood were detected by the immunoturbidimetric method.
|
on the third day before the treatment and the day before the operation
|
NE(µg/L)
Time Frame: on the third day before the treatment and the day before the operation
|
The blood of each group of patients was collected on the third day before the treatment and the day before the operation, and the levels of neurotransmitter indexes (5-HT, NE, GABA) in the peripheral blood were detected by the immunoturbidimetric method.
|
on the third day before the treatment and the day before the operation
|
GABA(µmol/L)
Time Frame: on the third day before the treatment and the day before the operation
|
The blood of each group of patients was collected on the third day before the treatment and the day before the operation, and the levels of neurotransmitter indexes (5-HT, NE, GABA) in the peripheral blood were detected by the immunoturbidimetric method.
|
on the third day before the treatment and the day before the operation
|
Chest tube removal time
Time Frame: up to 168 hours after surgery
|
Record the time from the end of surgery to the removal of chest tube.
|
up to 168 hours after surgery
|
Postoperative pain
Time Frame: up to 2 days after surgery
|
VAS ranges from 0 (no pain) to 10 (unbearable pain).
A change of 10 for the 100mm pain VAS signify a clinically important improvement or deterioration.
Participants will be asked to describe their average surgical incision intensity in the 48 hours after surgery.
|
up to 2 days after surgery
|
Length of postoperative hospital stay
Time Frame: up to 14 days after surgery
|
The length of postoperative stay will be recorded.
|
up to 14 days after surgery
|
Intraoperative anesthetic consumption
Time Frame: From the beginning to the end of the surgery
|
The types and cumulative doses of intraoperative analgesics will be assessed.
|
From the beginning to the end of the surgery
|
Collaborators and Investigators
Investigators
- Study Director: Jia Zhou, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20210427
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
- Analytic Code
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety
-
AstraZenecaCompletedAnxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety StatesUnited States
-
Prisma Health-UpstateCompletedAnxiety | Anxiety, Separation | Separation Anxiety | Anxiety Generalized
-
Ann & Robert H Lurie Children's Hospital of ChicagoUniversity of California, Los Angeles; University of CincinnatiRecruitingAnxiety, Separation | Anxiety, Social | Anxiety, GeneralizedUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)Active, not recruitingGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
Nazife Begüm KARANCompletedDental Anxiety | Sedative; Anxiety DisorderTurkey
-
Loyola UniversityCompletedAnxiety | Anxiety State | Procedural AnxietyUnited States
-
Eli Lilly and CompanyCompletedAnxiety Neuroses | Anxiety States, Neurotic | Neuroses, AnxietyUnited States, Mexico, South Africa
-
West University of TimisoaraUnknownAnxiety Disorder/Anxiety StateRomania
-
Dr. Nazanin AlaviActive, not recruitingGeneralized Anxiety Disorder | AnxietyCanada
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
Clinical Trials on TEAS
-
First Affiliated Hospital Xi'an Jiaotong UniversityCompletedPostoperative Nausea and VomitingChina
-
Air Force Military Medical University, ChinaCompletedSystemic Inflammatory Response Syndrome | InflammationChina
-
University of California, Los AngelesRecruitingConstipation - FunctionalUnited States
-
Zhihong LUCompletedRenal Function Disorder | Hepatic Dysfunction TransientChina
-
ShuGuang HospitalGuangdong Provincial People's HospitalCompleted
-
Xijing HospitalCompleted
-
Paula Witt-EnderbyDuquesne UniversityCompleted
-
ShangHai Ji Ai Genetics & IVF InstituteCompleted
-
Xijing HospitalNorthwest Women's and Children's Hospital, Xi'an, ShaanxiCompleted